

## 2015 (80)

Adissu HA, McKerlie C, Di Grappa M, Waterhouse P, Xu Q, Fang H, Khokha R, Wood GA. Timp3 loss accelerates tumour invasion and increases prostate inflammation in a mouse model of prostate cancer.. *Prostate*. 2015 Dec; 75 (16) 1831-1843

Akamatsu S, Wyatt AW, Lin D, Lysakowski S, Zhang F, KS, Tse C, Wang K, Mo F, Haegert A, Brahmhatt S, Bell R, Adomat H, Kawai Y, Xue H, Dong X, Fazli L, Tsai H, Lotan TL, Kossai M, Mosquera JM, Rubin MA, Beltran H, Zoubeidi A, Wang YZ, Gleave ME, Collins CC. The placental gene PEG10 promotes progression of neuroendocrine prostate cancer. *Cell Reports*. 2015 Aug; 12 (6) 922-936

Ali M, Daze KD, Strongin DE, Rothbart SB, Rincon-Arano H, Allen HF, Li J, Strahl BD, Hof F, Kutateladze TG. Molecular insights into inhibition of the methylated histone-plant homeodomain complexes by calixarenes. *Journal of Biological Chemistry*. 2015 Sep; 290 (38) 22919-22930

Alibhai SMH, Mina DS, Ritvo P, Sabiston C, Krahn M, Tomlinson G, Matthew A, Segal R, Warde P, Durbano S, O'Neill M, Culos-Reed N. A phase II RCT and economic analysis of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy. *BMC Cancer*. 2015 Apr; 15 312

Alioto TS, Buchhalter I, Derdak S, Hutter B, Eldridge MD, Hovig E, Heisler LE, Beck TA, Simpson JT, Tonon L, Sertier AS, Patch AM, Jager N, Ginsbach P, Drews R, Paramasivam N, Kabbe R, Chotewutmontri S, Diessl N, Previti C, Schmidt S, Brors B, Feuerbach L, Heinold M, Grobner S, Korshunov A, Tarpey PS, Butler AP, Hinton J, Jones D, Menzies A, Raine K, Shepherd R, Stebbings L, Teague JW, Ribeca P, Giner FC, Beltran S, Raineri E, Dabad M, Heath SC, Gut M, Denroche RE, Harding NJ, Yamaguchi TN, Fujimoto A, Nakagawa H, Quesada C, Valdes-Mas R, Nakken S, Vodak D, Bower L, Lynch AG, Anderson CL, Waddell N, Pearson JV, Grimmond SM, Peto M, Spellman P, He MH, Kandath C, Lee S, Zhang J, Letourneau L, Ma S, Seth S, Torrents D, Xi L, Wheeler DA, Lopez-Otin C, Campo E, Campbell PJ, Boutros PC, Puente XS, Gerhard DS, Pfister SM, McPherson JD, Hudson TJ, Schlesner M, Lichter P, Eils R, Jones DTW, Gut IG. A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. *Nature Communications*. 2015 Dec; 6 10001

Allaire J, Moreel X, Labonte ME, Leger C, Caron A, Julien P, Lamarche B, Fradet V. Validation of the omega-3 fatty acid intake measured by a web-based food frequency questionnaire against omega-3 fatty acids in red blood cells in men with prostate cancer. *European Journal of Clinical Nutrition*. 2015 Sep; 69 (9) 1004-1008

Anghel CV, Quon G, Haider S, Nguyen F, Deshwar AG, Morris QD, Boutros PC. ISOPureR: an R implementation of a computational purification algorithm of mixed tumour profiles. *BMC Bioinformatics*. 2015 May; 16 156

Astolfi M, Peant B, Lateef MA, Rousset N, Kendall-Dupont J, Carmona E, Monet F, Saad F, Provencher D, Mes-Masson AM, Gervais T. Micro-dissected tumor tissues on chip: an ex vivo method for drug testing and personalized therapy. *Lab on a Chip*. 2015 16 (2) 312-325

Azad Arun A, Volik Stanislav V, Wyatt Alexander W, Haegert Anne, Le Bihan Stephane, Bell Robert H, Anderson Shawn A, McConeghy Brian, Shukin Robert, Bazov Jenny, Youngren Jack, Paris Pamela, Thomas George, Small Eric J, Wang Yuzhuo, Gleave ME, Collins Colin C, Chi KN. Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer. *Clinical Cancer Research*. 2015 May; 21 2315-2324

Bailey Swneke D, Virtanen Carl, Haibe-Kains Benjamin, Lupien Mathieu. ABC: a tool to identify SNVs causing allele-specific transcription factor binding from CHIP-Seq experiments. *Bioinformatics*. 2015 Sep; 31 3057-3059

Bauregard JM, Blouin AC, Fradet V, Caron A, Fradet Y, Lemay C, Lacombe L, Dujardin T, Tiguert R, Rimac G, Bouchard F, Pouliot F. FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy. *Cancer Imaging*. 2015 Mar; 15 (2)

Bhindi B, Locke J, Alibhai SMH, Kulkarni GS, Margel DS, Hamilton RJ, Finelli A, Trachtenberg J, Zlotta AR, Toi A, Hersey KM, Evans A, van der Kwast TH, Fleshner NE. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort. *European Urology*. 2015 Jan; 67 (1) 64-70

Bishop JL, Davies A, Ketola K, Zoubeidi A. Regulation of tumor cell plasticity by the androgen receptor in prostate cancer. *Endocrine-Related Cancer*. 2015 Jun; 22 (3) R165-R182

Boutros PC, Fraser M, Harding NJ, de Borja R, Trudel D, Lalonde E, Meng A, Hennings-Yeomans PH, McPherson A, Sabelnykova VY, Zia AM, Fox NS, Livingstone J, Shiah YJ, Wang JX, Beck TA, Have CL, Chong T, Sam M, Johns J, Timms L, Buchner N, Wong A, Watson JD, Simmons TT, P'ng C, Zafarana G, Nguyen F, Luo XM, Chu KC, Prokopec SD, Sykes J, Dal Pra A, Berlin A, Brown A, Chan-Seng-Yue MA, Yousif F, Denroche RE, Chong LC, Chen GM, Jung E, Fung C, Starmans MHW, Chen H, Govind SK, Hawley J, D'Costa A, Pintilie M, Waggott D, Hach F, Lambin P, Muthuswamy LB, Cooper C, Eeles R, Neal D, Tetu B, Sahinalp C, Stein LD, Fleshner N, Shah SP, Collins CC, Hudson TJ, McPherson JD, van der Kwast T, Bristow RG. Spatial genomic heterogeneity within localized, multifocal prostate cancer. *Nature Genetics*. 2015 July; 47 (7) 736

Boutros PC. The path to routine use of genomic biomarkers in the cancer clinic. *Genome Research*. 2015 Oct; 25 (10) 1508-1513

Brett SI, KY, Biggs CN, Chin JL, Leong HS. Extracellular vesicles such as prostate cancer cell fragments as a fluid biopsy for prostate cancer. *Prostate Cancer and Prostatic Diseases*. 2015 Sep; 18 (3) 213-220

Butz H, Szabo PM, Khella HWZ, Nofech-Mozes R, Patocs A, Yousef GM. miRNA-target network reveals miR-124as a key miRNA contributing to clear cell renal cell carcinoma aggressive behaviour by targeting CAV1 and FLOT1. *Oncotarget*. 2015 May; 6 (14) 12543-12557

Chen S, Laverdiere I, Tourancheau A, Jonker D, Couture F, Cecchin E, Villeneuve L, Harvey M, Court MH, Innocenti F, Toffoli G, Levesque E, Guillemette C. A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patients.

Pharmacogenomics Journal. 2015 Dec; 15 (6) 513-520

Chen S, Villeneuve L, Jonker D, Couture F, Laverdiere I, Cecchin E, Innocenti F, Toffoli G, Levesque E, Guillemette C. ABCG5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients. *Pharmacogenetics and Genomics*. 2015 Dec; 25 (12) 573-583

Clermont PL, Lin D, Crea F, Wu R, Xue H, Wang YW, Thu KL, Lam WL, Collins CC, Wang YZ, Helgason CD. Polycomb-mediated silencing in neuroendocrine prostate cancer. *Clinical Epigenetics*. 2015 Apr; 7 40

Cooper CS, Eeles R, Wedge DC, Van Loo P, Gundem G, Alexandrov LB, Kremeyer B, Butler A, Lynch AG, Camacho N, Massie CE, Kay J, Luxton HJ, Edwards S, Kote-Jarai Z, Dennis N, Merson S, Leongamornlert D, Zamora J, Corbishley C, Thomas S, Nik-Zainal S, O'Meara S, Matthews L, Clark J, Hurst R, Mithen R, Bristow RG, Boutros PC, Fraser M, Cooke S, Raine K, Jones D, Menzies A, Stebbings L, Hinton J, Teague J, McLaren S, Mudie L, Hardy C, Anderson E, Joseph O, Goody V, Robinson B, Maddison M, Gamble S, Greenman C, Berney D, Hazell S, Livni N, Fisher C, Ogden C, Kumar P, Thompson A, Woodhouse C, Nicol D, Mayer E, Dudderidge T, Shah NC, Gnanapragasam V, Voet T, Campbell P, Futreal A, Easton D, Warren AY, Foster CS, Stratton MR, Whitaker HC, McDermott U, Brewer DS, Neal DE. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. *Nature Genetics*. 2015 Apr; 47 (4) 367-U118

Couture F, Ly K, Levesque C, Kwiatkowska A, Ait-Mohand S, Desjardins R, Guerin B, Day R. Multi-Leu PACE4 inhibitor retention within cells is PACE4-dependent and a prerequisite for antiproliferative activity. *Biomed Research International* . 2015; 824014

Crea F, Saidy NRN, Collins CC, Wang YZ. The epigenetic/noncoding origin of tumor dormancy. *Trends in Molecular Medicine*. 2015 Apr; 21 (4) 206-211

Creixell Pau, Reimand Jüri, Haider Syed, Wu Guanming, Shibata Tatsuhiro, Vazquez Miguel, Mustonen Ville, Gonzalez-Perez Abel, Pearson John, Sander Chris, Raphael Benjamin J, Marks Debora S, Ouellette B F Francis, Valencia Alfonso, Bader Gary D, Boutros Paul C, Stuart Joshua M, Linding Rune, Lopez-Bigas Nuria, Stein Lincoln D, Mutation Consequences and Pathway Analysis Working Group of the International Cancer Genome Consortium. Pathway and network analysis of cancer genomes. *Nature Methods*. 2015 July; 12 615-621

Cui LY, Lin QY, Jin CS, Jiang WL, Huang H, Ding LL, Muhanna N, Irish JC, Wang F, Chen J, Zheng G. A PEGylation-Free Biomimetic Porphyrin Nanoplatfor for Personalized Cancer Theranostics. *ACS Nano*. 2015 Apr; 9 (4) 4484-4495

Desmeules P, Hovington H, Nguile-Makao M, Leger C, Caron A, Lacombe L, Fradet Y, Tetu B, Fradet V. Comparison of digital image analysis and visual scoring of KI-67 in prostate cancer prognosis after prostatectomy. *Diagnostic Pathology*. 2015 Jun; 10

Donovan Kristine A, Walker Lauren M, Wassersug Richard J, Thompson Lora M A, Robinson John W. Psychological effects of androgen-deprivation therapy on men with prostate cancer and their

partners. *Cancer*. 2015 Dec; 121 4286-4299

Edgcumbe Philip, Pratt Philip, Yang Guang-Zhong, Nguan Christopher, Rohling Robert. Pico Lantern: Surface reconstruction and augmented reality in laparoscopic surgery using a pick-up laser projector. *Medical Image Analysis*. 2015 Oct; 25 95-102

Ewing AD, Houlahan KE, Hu Y, Ellrott K, Caloian C, Yamaguchi TN, Bare JC, P'ng C, Waggott D, Sabelnykova VY, Kellen MR, Norman TC, Haussler D, Friend SH, Stolovitzky G, Margolin AA, Stuart JM, Boutros PC. Combining tumor genome simulation with crowdsourcing to benchmark somatic single-nucleotide-variant detection. *Nature Methods*. 2015 July; 12 (7) 623

Fraser M, Berlin A, Bristow RG, van der Kwast T. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. *Urologic Oncology*. 2015 Feb; 33 (2) 85-94

Gani C, Coackley C, Kumareswaran R, Schutze C, Krause M, Zafarana G, Bristow RG. In vivo studies of the PARP inhibitor, AZD-2281, in combination with fractionated radiotherapy: An exploration of the therapeutic ratio. *Radiotherapy and Oncology*. 2015 Sep; 116 (3) 486-494

Grin A, Samaan S, Tripathi M, Rotondo F, Kovacs K, Bassily MN, Yousef GM. Evaluation of human tissue kallikrein-related peptidases 6 and 10 expression in early gastroesophageal adenocarcinoma. *Human Pathology*. 2015 Apr; 46 (4) 541-548

Hill J, Hackett C, Sloboda R, Menon G, Singhal S, Pervez N, Pedersen J, Yee D, Murtha A, Amanie J, Usmani N. Does location of prostate cancer by sextant biopsies predict for relapse after I-125 seed implant brachytherapy?. *Brachytherapy*. 2015 Nov-Dec; 14 (6) 788-794

Hollenberg MD. Proteinases, their receptors and inflammatory signalling: the Oxford South Parks Road connection. *British Journal of Pharmacology*. 2015 July; 172 (13) 3196-3211

Huang XY, Taeb S, Jahangiri S, Korpela E, Cadonic I, Yu N, Krylov SN, Fokas E, Boutros PC, Liu SK. miR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD). *Oncotarget*. 2015 Sep; 6 (26) 22439-22451

Kara I, Poggi M, Bonardo B, Govers R, Landrier JF, Tian S, Leibiger I, Day R, Creemers JWM, Peiretti F. The Paired Basic Amino Acid-cleaving Enzyme 4 (PACE4) Is Involved in the Maturation of Insulin Receptor Isoform B AN OPPORTUNITY TO REDUCE THE SPECIFIC INSULIN RECEPTOR-DEPENDENT EFFECTS OF INSULIN-LIKE GROWTH FACTOR 2 (IGF2). *Journal of Biological Chemistry*. 2015 Jan; 290 (5) 2812-2821

Karamchandani JR, Gabriel MY, Ibrahim R, Scorilas A, Filter E, Finelli A, Lee JY, Ordon M, Pasic M, Romaschin AD, Yousef GM. Profilin-1 expression is associated with high grade and stage and decreased disease-free survival in renal cell carcinoma. *Human Pathology*. 2015 May; 46 (5) 673-680

Kerns SL, Kundu S, Oh JH, Singhal SK, Janelins M, Travis LB, Deasy JO, Janssens ACJE, Ostrer H, Parliament M, Usmani N, Rosenstein BS. The prediction of radiotherapy toxicity using single

nucleotide polymorphism-based models: a step toward prevention. *Seminars in Radiation Oncology*. 2015 Oct; 25 (4) 281-291

Khella HWZ, Butz H, Ding Q, Rotondo F, Evans KR, Kupchak P, Dharsee M, Latif A, Pasic MD, Lianidou E, Bjarnason GA, Yousef GM. miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma. *Molecular Therapy*. 2015 Nov; 23 (11) 1748-1758

Khella HWZ, Scorilas A, Mozes R, Mirham L, Lianidou E, Krylov SN, Lee JY, Ordon M, Stewart R, Jewett MAS, Youseff GM. Low Expression of miR-126 Is a Prognostic Marker for Metastatic Clear Cell Renal Cell Carcinoma. *American Journal of Pathology*. 2015 Mar; 185 (3) 693-703

Klotz L. Defining 'progression' and triggers for curative intervention during active surveillance. *Current Opinion in Urology*. 2015 May; 25 (3) 258-266

Korpela E, Vesprini D, Liu SK. MicroRNA in radiotherapy: miRage or miRador?. *British Journal of Cancer*. 2015 Mar; 112 (5) 777-782

Laverdiere I, Guillemette C, Tamouza R, Loiseau P, de Latour RP, Robin M, Couture F, Filion A, Lalancette M, Tourancheau A, Charron D, Socie G, Levesque E. Cyclosporine and methotrexate-related pharmacogenomic predictors of acute graft-versus-host disease. *Haematologica*. 2015 Feb; 100 (2) 275-283

Leclerc BG, Charlebois R, Chouinard G, Allard B, Pommey S, Saad F, Stagg J. CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer. *Clinical Cancer Research*. 2015 Jan; 22 (1) 158-166

Lee A, Dong X. Driver or passenger - roles of the glucocorticoid receptor in castration resistance prostate cancers. *Receptors and Clinical Investigation*. 2015 2 (1)

Lee SL, Yu D, Wang C, Saba R, Liu SH, Trpkov K, Donnelly B, Bismar TA. ERG Expression in Prostate Needle Biopsy: Potential Diagnostic and Prognostic Implications. *Applied Immunohistochemistry and Molecular Morphology*. 2015 Aug; 23 (7) 499-505

Lelj-Garolla B, Kumano M, Beraldi E, Nappi L, Rocchi P, Ionescu DN, Fazli L, Zoubeidi A, Gleave ME. Hsp27 Inhibition with OGX-427 Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy. *Molecular Cancer Therapeutics*. 2015 May; 14 (5) 1107-1116

Levesque C, Couture F, Kwiatkowska A, Desjardins R, Guerin B, Neugebauer WA, Day R. PACE4 inhibitors and their peptidomimetic analogs block prostate cancer tumor progression through quiescence induction, increased apoptosis and impaired neovascularisation. *Oncotarget*. 2015 Feb; 6 (6) 3680-3693

Li HL, Xie N, Gleave ME, Dong XS. Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression. *Oncotarget*. 2015 Aug; 6 (24) 20474-20484

Li YA, Xie N, Gleave ME, Rennie PS, Dong XS. AR-v7 protein expression is regulated by protein kinase

and phosphatase. *Oncotarget*. 2015 Oct; 6 (32) 33743-33754

Lichner Z, Ding Q, Samaan S, Saleh C, Nasser A, Al-Haddad S, Samuel JN, Fleshner NE, Stephan C, Jung K, Yousef GM. miRNAs dysregulated in association with Gleason grade regulate extracellular matrix, cytoskeleton and androgen receptor pathways. *Journal of Pathology*. 2015 Oct; 237 (2) 226-237

Lichner Z, Saleh C, Subramaniam V, Seivwright A, Prud'homme GJ, Yousef GM. miR-17 inhibition enhances the formation of kidney cancer spheres with stem cell/tumor initiating cell properties. *Oncotarget*. 2015 Mar; 6 (8) 5567-5581

Lin D, Dong X, Wang K, Wyatt AW, Crea F, Xue H, Wang YW, Wu R, Bell RH, Haegert A, Brahmabhatt S, Hurtado-Coll A, Gout PW, Fazli L, Gleave ME, Collins CC, Wang YZ. Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer. *Oncotarget*. 2015 Jan; 6 (3) 1806-1820

Liu LL, Li HL, Dargahi D, Shynlova O, Slater D, Jones SJM, Lye SJ, Dong XS. HoxA13 Regulates Phenotype Regionalization of Human Pregnant Myometrium. *Journal of Clinical Endocrinology and Metabolism*. 2015 Dec; 100 (12) E1512-E1522

Locke JA, Dal Pra A, Supiot S, Warde P, Bristow RG. Synergistic action of image-guided radiotherapy and androgen deprivation therapy. *Nature Reviews Urology*. 2015 Apr; 12 (4) 193-204

Meng FR, Joshi B, Nabi IR. Galectin-3 Overrides PTRF/Cavin-1 Reduction of PC3 Prostate Cancer Cell Migration. *PLoS One*. 2015 May; 10 e0126056

Mina DS, Au D, Alibhai SMH, Jamnicky L, Faghani N, Hilton WJ, Stefanyk LE, Ritvo P, Jones J, Elterman D, Fleshner NE, Finelli A, Singal RK, Trachtenberg J, Matthew AG. A pilot randomized trial of conventional versus advanced pelvic floor exercises to treat urinary incontinence after radical prostatectomy: a study protocol. *BMC Urology*. 2015 Sep; 15 94

Murashima Aki, Kishigami Satoshi, Thomson Axel, Yamada Gen. Androgens and mammalian male reproductive tract development. *Biochimica et Biophysica Acta - Gene Regulatory Mechanisms*. 2015 Feb; 1849 163-170

Ng KK, Takada M, Jin CCS, Zheng G. Self-Sensing Porphysomes for Fluorescence-Guided Photothermal Therapy. *Bioconjugate Chemistry*. 2015 Feb; 26 (2) 345-351

Ng KK, Zheng G. Molecular Interactions in Organic Nanoparticles for Phototheranostic Applications. *Chemical Reviews*. 2015 Oct; 115 (19) 11012-11042

Paproski R, Forbrich A, Huynh E, Chen J, Lewis J, Zheng G, Zemp R. Porphyrin Nanodroplets: Sub-micrometer Ultrasound and Photoacoustic Contrast Imaging Agents. *Small*. 2015 Jan; 12 (3) 371-380

Parolia A, Crea F, Xue H, Wang YW, Mo F, Ramnarine VR, Liu HH, Lin D, Saidy NRN, Clermont PL, Cheng HW, Collins C, Wang YZ, Helgason CD. The long non-coding RNA PCGEM1 is regulated by androgen receptor activity in vivo. *Molecular Cancer*. 2015 Feb; 14 46

Qin X, Park S, Duffy SP, Matthews K, Ang RR, Todenhofer T, Abdi H, Azad A, Bazov J, Chi KN, Black PC, Ma HS. Size and deformability based separation of circulating tumor cells from castrate resistant prostate cancer patients using resettable cell traps. *Lab on a Chip*. 2015 15 (10) 2278-2286

Quanico J, Franck J, Gimeno JP, Sabbagh R, Salzet M, Day R, Fournier I. Parafilm-assisted microdissection: a sampling method for mass spectrometry-based identification of differentially expressed prostate cancer protein biomarkers. *Chemical Communications*. 2015 51 (22) 4564-4567

Sadeghi-Naini A, Sofroni E, Papanicolau N, Falou O, Sugar L, Morton G, Yaffe MJ, Nam R, Sadeghian A, Kolios MC, Chung HT, Czarnota GJ. Quantitative ultrasound spectroscopic imaging for characterization of disease extent in prostate cancer patients. *Translational Oncology*. 2015 Feb; 8 (1) 25-34

Salanti Ali, Clausen Thomas M, Agerbæk Mette Ø, Al Nakouzi Nader, Dahlbäck Madeleine, Oo Htoo Z, Lee Sherry, Gustavsson Tobias, Rich Jamie R, Hedberg Bradley J, Mao Yang, Barington Line, Pereira Marina A, LoBello Janine, Endo Makoto, Fazli Ladan, Soden Jo, Wang Chris K, Sander Adam F, Dagil Robert, Thrane Susan, Holst Peter J, Meng Le, Favero Francesco, Weiss Glen J, Nielsen Morten A, Freeth Jim, Nielsen Torsten O, Zaia Joseph, Tran Nhan L, Trent Jeff, Babcock John S, Theander Thor G, Sorensen Poul H, Daugaard Mads. Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein. *Cancer Cell*. 2015 Oct; 28 500-514

Santa Mina Daniel, Scheede-Bergdahl Celena, Gillis Chelsia, Carli Francesco. Optimization of Surgical Outcomes with Prehabilitation. *Applied Physiology Nutrition and Metabolism*. 2015 Sep; 40 966-969

Shao P, Chapman DW, Moore RB, Zemp RJ. Monitoring photodynamic therapy with photoacoustic microscopy. *Journal of Biomedical Optics*. 2015 Oct; 20 106012

Somasekharan SP, El-Naggar A, Leprivier G, Cheng HW, Hajee S, Grunewald TGP, Zhang F, Ng T, Delattre O, Evdokimova V, Wang YZ, Gleave M, Sorensen PH. YB-1 regulates stress granule formation and tumor progression by translationally activating G3BP1. *Journal of Cell Biology*. 2015 Mar; 208 (7) 913-929

Stoletov K, Lewis JD. Invadopodia: a new therapeutic target to block cancer metastasis. *Expert Review of Anticancer Therapy*. 2015 15 (7) 733-735

Tan Q, Joshua AM, Saggar JK, Yu M, Wang M, Kanga N, Zhang JY, Chen X, Wouters BG, Tannock IF. Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy. *British Journal of Cancer*. 2015 Mar; 112 832-840

Tang Y, Bhandaru M, Cheng YB, Lu J, Li G, Ong CJ. The role of the metastasis suppressor gene KAI1 in melanoma angiogenesis. *Pigment Cell and Melanoma Research*. 2015 Nov; 28 (6) 696-706

Trinh L, Arbour-Nicitopoulos KP, Sabiston CM, Alibhai SM, Jones JM, Berry SR, Loblaw A, Faulkner GE. A qualitative study exploring the perceptions of sedentary behaviour in prostate cancer survivors receiving androgen-deprivation therapy. *Oncology Nursing Forum*. 2015 July; 42 (4) 398-406

van Gisbergen MW, Voets AM, Starmans M H W, de Coo I F M, Yadak R, Hoffmann RF, Boutros PC, Smeets H J M, Dubois L, Lambin P. How do changes in the mtDNA and mitochondrial dysfunction influence cancer and cancer therapy? Challenges, opportunities and models. *Mutation Research/Reviews in Mutation Research*. 2015; 764 16-30

Veisheh Mandana, Leith Sean J, Tolg Cornelia, Elhayek Sallie S, Bahrami S Bahram, Collis Lisa, Hamilton Sara, McCarthy James B, Bissell Mina J, Turley Eva. Uncovering the dual role of RHAMM as an HA receptor and a regulator of CD44 expression in RHAMM-expressing mesenchymal progenitor cells. *Frontiers in Cell and Developmental Biology*. 2015; 3 63

Wala SJ, Karamchandani JR, Saleeb R, Evans A, Ding Q, Ibrahim R, Jewett M, Pasic M, Finelli A, Pace K, Lianidou E, Yousef GM. An integrated genomic analysis of papillary renal cell carcinoma type 1 uncovers the role of focal adhesion and extracellular matrix pathways. *Molecular Oncology*. 2015 Oct; 9 (8) 1667-1677

White-Al Habeeb NM, Di Meo A, Scorilas A, Rotondo F, Masui O, Seivwright A, Gabriel M, Girgis AHA, Jewett MA, Yousef GM. Alpha-enolase is a potential prognostic marker in clear cell renal cell carcinoma. *Clinical and Experimental Metastasis*. 2015 Aug; 32 (6) 531-541

Wyatt Alexander W, Gleave ME. Targeting the adaptive molecular landscape of castration-resistant prostate cancer. *EMBO Molecular Medicine*. 2015 July; 7 878-894

Yamamoto Y, Lorient Y, Beraldi E, Zhang F, Wyatt AW, Al Nakouzi N, Mo F, Zhou TY, KY, Monia BP, MacLeod AR, Fazli L, Wang YZ, Collins CC, Zoubeidi A, Gleave M. Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth. *Clinical Cancer Research*. 2015 Apr; 21 (7) 1675-1687

Yu Y, Yang O, Fazli L, Rennie PS, Gleave ME, Dong XS. Progesterone receptor expression during prostate cancer progression suggests a role of this receptor in stromal cell differentiation. *Prostate*. 2015 July; 75 (10) 1043-1050